Tenofovir disoproxil fumarate-induced severe liver injury in a patient with chronic hepatitis B virus infection

Kang, Min Kyu; Park, Jung Gil

doi:10.1016/j.dld.2018.03.013

Cited by 3 publications

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are no persuasive reports about the attribution of liver injury of tenofovir. However, the tenofovir combination with didanosine leads to liver injury along with microvesicular fatty liver disease and lactic acidosis more commonly than didanosine with other antiretrovirals, which is due to drug-drug interactions [29,30]. Liu et al suggested many drugs as the candidates against 2019-nCoV [31].…”

Section: Introductionmentioning

confidence: 99%

DFT, molecular docking and ADME prediction of tenofovir drug as a promising therapeutic inhibitor of SARS-CoV-2 Mpro

Shahab

Sheikhi

Khancheuski

et al. 2023

MGC

View full text Add to dashboard Cite

In the present work, at first, DFT calculations were carried out to study the molecular structure of the tenofovir at B3LYP/MidiX level of theory and in the water as solvent. The HOMO/LUMO molecular orbitals, excitation energies and oscillator strengths of investigated drug were also calculated and presented. NBO analysis was performed to illustrate the intramolecular rehybridization and electron density delocalization. In the following, a molecular docking study was performed for screening of effective available tenofovir drug which may act as an efficient inhibitor for the SARS-CoV-2 Mpro. The binding energy value showed a good binding affinity between the tenofovir and SARS-CoV-2 Mpro with binding energy of-47.206 kcal/mol. Therefore, tenofovir can be used for possible application against the SARS-CoV-2 Mpro.

show abstract

Section: Introductionmentioning

confidence: 99%

DFT, molecular docking and ADME prediction of tenofovir drug as a promising therapeutic inhibitor of SARS-CoV-2 Mpro

Shahab

Sheikhi

Khancheuski

et al. 2023

MGC

View full text Add to dashboard Cite

show abstract

Tenofovir disoproxil fumarate

2018

Reactions Weekly

View full text Add to dashboard Cite

Features of liver ultrastructure of rat exposed by antiretroviral drug tenofovir disoproxil fumarate in combination with S-adenosylmethionine

Астроўская

Краўчук

Курбат

2020

Vescì Nac. akad. navuk Belarusì, Ser. med. navuk

View full text Add to dashboard Cite

Ultrastructural changes in the liver of rats after 7and 21-days intragastric administration of tenofovir disoproxil fumarate (TDF) at a dose of 50 mg/kg/daily and correction of the revealed violations by S-adenosylmethionine (SAM) were described. Exposure of TDF for 7 days causes mild dystrophic changes in a small proportion of hepatocytes. The 21-day effect of TDF in the hepatocytes of the periportal zones shows the development of moderately pronounced dystrophy with a decrease in protein-synthetic function and slight changes in the structure of mitochondria. At both periods of administration, TDF leads to the death of single cells of the liver parenchyma and reactive intralobular inflammatory infiltration. The use of SAM on long-term administration of TDF does not reduce the intensity of core liver infiltration, but prevents the development of dystrophy of peripоrtal hepatocytes and normalizes the amount of lipid inclusions in parenchymal cells of the organ.

show abstract

Tenofovir disoproxil fumarate-induced severe liver injury in a patient with chronic hepatitis B virus infection

Cited by 3 publications

References 7 publications

DFT, molecular docking and ADME prediction of tenofovir drug as a promising therapeutic inhibitor of SARS-CoV-2 Mpro

DFT, molecular docking and ADME prediction of tenofovir drug as a promising therapeutic inhibitor of SARS-CoV-2 Mpro

Tenofovir disoproxil fumarate

Features of liver ultrastructure of rat exposed by antiretroviral drug tenofovir disoproxil fumarate in combination with S-adenosylmethionine

Contact Info

Product

Resources

About